United States · Investor

Apple Tree Partners

Last cheque observed Sep 2025. Silence since then is not evidence of inactivity: our sources miss unannounced rounds.

QuietNew fund $14M, Nov 2013VC firm

SeedSeries ASeries BHealthcareMental HealthMolecules

Cheques on record
0%of best year0cheques in 12 months, 28 on record
Since the last cheque417days00hrs00min00sec
Median round$60MCheque size, as they say$100K – $5.0MRounds led0 of 28Sole investor5 roundsExits3 from the portfolioMostly inUnited States, 96%
Pitch Apple Tree Partners

Apple Tree Partners highlights

  1. 01

    28 rounds on record

  2. 02

    Mostly Series B and Series D: 50% of its rounds

  3. 03

    Sole investor in 5 rounds, median $40M

  4. 04

    3 exits from the portfolio

What they do

Apple Tree Partners (ATP). a pioneer in life sciences venture capitalFrom their own website
Type
VC firm (from a list, unverified)
Cheque size
$100K – $5.0M as they say
Stages
SeedSeries ASeries BGrowth
Sectors
HealthcareMental HealthMolecules
Based in
New York, United States
Cold pitches
Not stated

The record

Every round we can evidence, newest first28 appearances

  1. 2025

    1 round

  2. Sept
    Galvanize Therapeutics, IncSeries C · US · Elevage Medical Technologies$100MWith 10 others
  3. 2019

    1 round

  4. Dec
    Limelight BioUS · FinSMEs$75MSole investor
  5. 2018

    4 rounds

  6. Dec
    Akero TherapeuticsSeries B · US · FinSMEs$70MWith 9 others
  7. Jun
    Akero TherapeuticsSeries A · US · FinSMEs$65MWith 3 others
  8. Apr
    CorvidiaSeries B · US · FinSMEs$60MWith 8 others
  9. Jan
    BraeburnDebt · US · FinSMEs$110MWith 6 others
  10. 2017

    3 rounds

  11. Jun
    SyntimmuneSeries B · US · FinSMEs$50MSole investor
  12. Jan
    Stoke TherapeuticsSeries A · US · FinSMEs$40MSole investor
  13. Jan
    ElstarSeries A · US · FinSMEs$39MSole investor
  14. 2016

    2 rounds

  15. Sept
    ROX MedicalSeries E · US · FinSMEs$40MWith 1 other
  16. Jul
    VytronUSSeries C · US · FinSMEs$49MWith 2 others
  17. 2014

    6 rounds

  18. Oct
    Aileron TherapeuticsSeries E · US$33MWith 6 others
  19. Oct
    VytronUSSeries B · US$32MWith 2 others
  20. Aug
    DermiraSeries C · US$51MWith 7 others
  21. Jul
    CerecorSeries B · US$32MWith 2 others
  22. Apr
    Tendyne HoldingsSeries C · US$25MSole investor
  23. Feb
    Aurinia PharmaceuticalsCA$52MWith 8 others
  24. 2013

    3 rounds

  25. Nov
    Aileron TherapeuticsSeries E · US · finsmes.com$30MWith 5 others
  26. May
    Tokai PharmaceuticalsSeries E · US · fiercebiotech.com$36MWith 1 other
  27. Jan
    Aileron TherapeuticsSeries D · US · finsmes.com$12MWith 5 others
  28. 2011

    1 round

  29. Sept
    Tokai PharmaceuticalsSeries D · US · eon.businesswire.com$23MWith 1 other
  30. 2009

    3 rounds

  31. Aug
    Gloucester PharmaceuticalsSeries D · US · gloucesterpharma.com$29MWith 4 others
  32. Jun
    Aileron TherapeuticsSeries D · US · zibb.com$40MWith 6 others
  33. Jun
    Tokai PharmaceuticalsSeries D · US · onbiovc.com$22MWith 1 other
  34. 2008

    1 round

  35. Apr
    Aileron TherapeuticsSeries B · US · boston.bizjournals.com$11MWith 1 other
  36. 2007

    1 round

  37. Jun
    Aileron TherapeuticsSeries B · US$7.0MWith 1 other
  38. 2006

    1 round

  39. Dec
    Aileron TherapeuticsSeries A · US · fiercebiotech.com$7.0MWith 1 other
  40. 2000

    1 round

  41. Mar
    Cyrano SciencesVenture · US$23MWith 6 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

The team

Named by the firm itself, on a filing, its Form ADV or its company registration1 named

SLSeth L. HarrisonExecutive OfficeriFiling they signed

We also hold 17 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

What the register says

From the firm's own filings with the SEC, which it must file accurately by law

$3.6Bgross assets of its fundsOct 2026
Exemptreporting adviserventure or small private funds
Legal name
Apple TREE Venture Management LLC
SEC number
CRD 163705

What they claim to have backed

From their own portfolio page (on their website)

1 of 16 we have independently watched raise

company'scompany'scompany'scompany'scompany'scompany'scompany'scompany'scompany'scompany'scompany'scompany'scompany'scompany'scompany'scompany's

Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.

Exits from the portfolio

Companies it backed that were later bought or listed3 in all

Tendyne HoldingsBought by Abbott Labs$250MJul 2015
Gloucester PharmaceuticalsBought by Celgene$640MDec 2009
Cyrano SciencesBought by Smiths DetectionUndisclosedMar 2004

An exit counts when it came after the firm's first round in the company. From historical deal records.

Who they invest alongside

The investors most often in the same rounds as Apple Tree Partners. A count of rooms they were both in, not a relationship either has claimed.

Novartis Venture FundCorporate VC11rounds togetherExcel Venture ManagementVC firm4rounds togetherNew Enterprise AssociatesVC firm4rounds togetherRoche Venture FundCorporate VC4rounds togetherSR OneCorporate VC4rounds togetherLilly VenturesCorporate VC3rounds togethervenBio PartnersVC firm3rounds togetherAtlasPrivate equity2rounds togetherBioStar VenturesVC firm2rounds togetherCanaanVC firm2rounds togetherCormorant CapitalVC firm2rounds togetherRA Capital ManagementPrivate equity2rounds together

Recently backed

The latest companies Apple Tree Partners put money into.

Akero Therapeutics$70M · Dec 2018Braeburn$110M · Jan 2018Syntimmune$50M · Jun 2017Stoke Therapeutics$40M · Jan 2017VytronUS$49M · Jul 2016

Quick answers about Apple Tree Partners

What does Apple Tree Partners invest in?

Apple Tree Partners invests most often at Series B and Series D (50% of the rounds on record), in sectors such as Healthcare, Mental Health and Molecules.

How active is Apple Tree Partners?

28 investments on record, 0 of them in the last 12 months. The most recent was in Sept 2025.

What has Apple Tree Partners invested in recently?

Its most recent investments on record: Galvanize Therapeutics, Inc (Series C, Sept 2025), Limelight Bio (Undisclosed round, Dec 2019) and Akero Therapeutics (Series B, Dec 2018).

How big are Apple Tree Partners's cheques?

The median round it joins is $60M. It says it writes cheques of $100K to $5.0M.

Does Apple Tree Partners lead rounds?

Rarely, if at all: none of its 28 investments on record names it as the lead.

Where does Apple Tree Partners invest?

Most of the companies it backs are in the United States (96%).

Is Apple Tree Partners investing now?

No investments in the last 12 months; the latest was in Sept 2025.

Who does Apple Tree Partners invest alongside?

Most often Novartis Venture Fund (11 rounds together), Excel Venture Management (4 rounds together) and New Enterprise Associates (4 rounds together).

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it